Intensity Therapeutics INTS
NASDAQ INTS
$3.42 -0.23 (-6.28%)
As of: Sep 29, 2026 · 3:55 PM EDT

Intensity Therapeutics (INTS) Liabilities and Shareholders Equity (2022 - 2026)

Updated

Intensity Therapeutics (INTS) posted Liabilities and Shareholders Equity of $11.52 million for Q2 2026, up 159.3% from $4.44 million a year earlier but down 6.3% from the prior quarter.

Analysis

Intensity Therapeutics (INTS) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends

At the end of FY2025, Intensity Therapeutics' Liabilities and Shareholders Equity came in at $14.1 million, up 194.8% from FY2024.

  • Annual Liabilities and Shareholders Equity shows a three-year compound annual growth rate of 100.2% (FY2022 to FY2025).
  • In prior years, Intensity Therapeutics' Liabilities and Shareholders Equity was $4.78 million in FY2024 (-72.3%), $17.3 million in FY2023 (+884.3%) and $1.76 million in FY2022.
  • Quarterly Liabilities and Shareholders Equity has run from a low of $1.76 million in Q4 2022 to a high of $18.23 million in Q2 2023 over five years.
  • On a year-over-year basis, Liabilities and Shareholders Equity has increased in each of the last four quarters, with growth averaging 59.2% over the last eight quarters.
  • The strongest year-over-year quarter for Liabilities and Shareholders Equity in the past five years was Q4 2023, with growth of 884.3%; the weakest was Q1 2025, with a decline of 75.3%.
  • According to Business Quant data, Liabilities and Shareholders Equity for the three prior quarters was $12.29 million (Q1 2026), $14.1 million (Q4 2025) and $9.59 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 201.06 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 135.12 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 115.83 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 49.36 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 27.42 Bn
10 Intensity Therapeutics 10.75 Mn 10.75 Mn - 11.52 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 11.52 Mn
Mar 31, 2026 12.29 Mn
Dec 31, 2025 14.10 Mn
Sep 30, 2025 9.59 Mn
Jun 30, 2025 4.44 Mn
Mar 31, 2025 3.07 Mn
Dec 31, 2024 4.78 Mn
Sep 30, 2024 5.21 Mn
Jun 30, 2024 8.67 Mn
Mar 31, 2024 12.41 Mn
Dec 31, 2023 17.30 Mn
Sep 30, 2023 16.82 Mn
Jun 30, 2023 18.23 Mn
Dec 31, 2022 1.76 Mn
API Access

Intensity Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=INTS&period=max&api_key=YOUR_API_KEY